Tidewave Bio

What Tidewave Bio does

Tidewave Bio is a preclinical-stage biotechnology company developing a universal, off-the-shelf dendritic cell immunotherapy platform for the treatment of solid tumors. Founded in 2025 and headquartered in Los Angeles, the company combines a universal gene-enhanced antigen-presenting cell product — derived from allogeneic hematopoietic stem cells and engineered to secrete CXCL9/10 signaling molecules — with a patient-specific tumor antigen sample prepared in real time from a biopsy using a disposable device. The resulting personalized therapy is administered intradermally at the point of care and is designed to address solid tumor heterogeneity, overcome immune evasion, and induce durable immune memory across multiple cancer types including melanoma, breast, gynecological, and hepatobiliary cancers.

The company's core intellectual property is grounded in patent applications covering gene-modified dendritic cell technology, supported by published research in Cell Reports Medicine and complemented by technology developed at UCLA in the Dean of Medical School's lab. Tidewave Bio is led by co-founders François Binette (CEO, former President of Renovaro Biosciences and Global Head of Product Development at Lineage Cell Therapeutics, with 30 years of cell and gene therapy experience) and Michael Montgomery (CMO, former leader of Global Medical Affairs at Incyte and co-founder of the J&J Proof-of-Concept Team). The Clinical Advisory Board is headed by Prof. Alexander Eggermont, former Director General of Gustave Roussy with more than 1,200 publications, with additional advisors covering translational science, clinical oncology, scientific strategy, and biopharmaceutical operations.

Tidewave Bio does not currently generate revenue and is pre-commercial. Its intended go-to-market model is direct enterprise sales to cancer treatment centers and oncology hospitals, where the universal cell product would be stored on site and combined with patient biopsy material at the point of care, bypassing traditional pharmacy distribution. Pricing has not been disclosed. The company states plans to file for clinical trial authorization in the near term and frames its addressable opportunity as 10–100x the current ~$4B CAR-T market, given that solid tumors represent approximately 90% of all cancer cases versus the ~10% addressable by current hematological cancer therapies.

Name

Tidewave Bio

Legal name

Tidewave Bio

Website

https://tidewavebio.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Tidewave Bio is a preclinical-stage biotechnology company developing a universal, off-the-shelf gene-modified dendritic cell immunotherapy platform for solid tumor patients, personalized in real time at the point of care using patient biopsy material.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy / Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Dendritic Cell & Other APC-based Therapies (HLAAABAF)

akta.pro secondary industries

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Cancer immunotherapy
• Dendritic cell therapy
• Solid tumor treatment
• Allogeneic cell therapy
• Cell therapy platform

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Cell therapy product revenue: As a preclinical biotech with therapies in development, Tidewave Bio does not yet generate revenue. The intended revenue stream is the sale of its universal dendritic cell immunotherapy product to cancer centers and healthcare systems upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Tidewave Bio is developing a universal, off-the-shelf dendritic cell immunotherapy product for solid tumors. The platform combines gene-enhanced antigen-presenting cells (engineered with CXCL9/10 modifications and derived from allogeneic hematopoietic stem cells) with a patient-specific tumor antigen sample prepared in real time at the point of care from a diagnostic biopsy using a disposable device. The personalized therapy is then administered via intradermal injection, designed to overcome solid tumor immune evasion and induce durable immune memory.

Product overview

Tidewave Bio offers a single unified platform — the Universal Dendritic Cell Immunotherapy Platform — consisting of gene-enhanced antigen-presenting cells (derived from allogeneic hematopoietic stem cells) that are combined with patient-specific tumor antigens in real time at the point of care. The platform uses CXCL9/10 gene modifications to overcome solid tumor immune escape and induce durable systemic immune responses. The therapy is stored off-the-shelf and becomes patient-personalized upon combination with a tumor biopsy using a disposable device system.

Differentiator

Problem solved

Functional benefit

Products and services

• Universal Dendritic Cell Immunotherapy Platform A universal, off-the-shelf dendritic cell immunotherapy product engineered with CXCL9/10 gene modifications and derived from allogeneic hematopoietic stem cells. The universal cell product is stored on site at cancer centers and combined at point of care with patient-specific tumor antigens prepared in real time from a diagnostic biopsy using a disposable device, then administered via intradermal injection. It is designed to treat solid tumor patients (including melanoma, breast, gynecological, and hepatobiliary cancers) across all solid tumor types without patient pre-selection, overcoming immune evasion and inducing durable immune memory.

Quantifiable outcome

• Addresses 90% of all cancer cases (solid tumors) compared to CAR-T which addresses only ~10% (hematological cancers)
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• UCLA (Dean of Medical School's lab)coreTechnology or IntegrationTidewave Bio's technology is complemented by technology developed at UCLA in the Dean of Medical School's lab, forming a foundational element of the company's intellectual property portfolio.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Dendreon Pharmaceuticals: Dendreon commercialized the first FDA-approved autologous cellular immunotherapy (sipuleucel-T/Provenge) for prostate cancer. As a precedent for dendritic cell-based cancer immunotherapy and CMC operations, Dendreon provides relevant operational and regulatory context for Tidewave.
• Allogene Therapeutics: Allogene is a clinical-stage leader in allogeneic CAR-T cell therapy. While primarily focused on hematologic cancers, Allogene's allogeneic manufacturing platform and scale provide a useful precedent for Tidewave's universal off-the-shelf model, though Tidewave's dendritic cell approach is structurally different.
• Lineage Cell Therapeutics: Lineage develops allogeneic cell therapies including stem cell-derived therapies for oncology and neurology. Tidewave's CEO François Binette was previously Global Head of Product Development at Lineage, and both companies share expertise in allogeneic cell therapy manufacturing and scale.

Direct peers

• Fate Therapeutics: Fate Therapeutics develops off-the-shelf iPSC-derived NK and T cell therapies for cancer. Both companies share the off-the-shelf allogeneic manufacturing model and are engineering cell therapies to address solid tumor heterogeneity and immune evasion.
• Adaptimmune Therapeutics: Adaptimmune develops engineered TCR-T cell therapies targeting solid tumors (e.g., Tecelra for synovial sarcoma). Both companies are pursuing cell-based therapies for solid tumors with engineering approaches designed to overcome immune evasion, though Adaptimmune uses TCR-T rather than dendritic cells.
• Turnstone Biologics: Turnstone develops tumor-infiltrating lymphocyte (TIL) and vaccinia virus-based immunotherapies for solid tumors. Both companies are engineering combination immunotherapies designed to drive durable T-cell responses against solid tumors.
• Lyell Immunopharma: Lyell is developing next-generation TIL and CAR-T cell therapies engineered to overcome T-cell exhaustion in solid tumors. The exhaustion-resilience thesis is conceptually adjacent to Tidewave's CXCL9/10 approach to immune evasion, although Lyell uses different cell types and modalities.
• Iovance Biotherapeutics: Iovance develops autologous tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors, with lifileucel approved for advanced melanoma. It is the closest commercial-stage analog to Tidewave's solid tumor cell therapy thesis, though Tidewave's allogeneic dendritic cell approach is fundamentally different from TIL.
• Nkarta: Nkarta develops allogeneic NK cell therapies engineered with CARs and other modifications for solid tumors and hematologic malignancies. Both companies pursue engineered, off-the-shelf cell therapies designed to overcome solid tumor immune evasion.

Emerging players

• Shoreline Biosciences: Shoreline develops iPSC-derived allogeneic NK cell therapies for cancer. Like Tidewave, Shoreline pursues an off-the-shelf engineered cell therapy approach, but Shoreline's NK cell platform is at an earlier clinical stage and focuses on hematologic and select solid tumor indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/tidewave-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tidewave Bio